Sandoz Inaugurates BioInject – a new state-of-the-art biopharmaceutical manufacturing facility in Schaftenau, Austria

  • Sandoz is investing over 150 million euro and creating 100 new highly qualified jobs
  • The new BioInject facility will support Sandoz’s fast growing biosimilars business as well as other Novartis biologics
  • State-of-the-art technology will strengthen Sandoz and Novartis in-house capabilities in drug product manufacturing

Schaftenau, September 17 2015 – Sandoz, the generics and biosimilars business of Novartis, today officially opened its new cutting-edge biomanufacturing facility called BioInject, at Schaftenau in the Tyrolean Alps in Austria …

/by